IP Library Granted Patent US 9,127,090
Granted Patent B2
US 9,127,090 · App. 13/172,605 · Granted Sep 8, 2015

Artificial antibody polypeptides

Inventor: Shohei Koide (Rochester, NY)
Assignee: Novartis AG
C07K14/78C07K16/00C07K16/18C07K16/40C12N15/1037C12N15/1044C40B40/02G01N33/68G01N33/6845C07K2317/565C07K2318/20G01N33/78G01N2333/78
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,127,090
App. No.
13/172,605
Granted
Sep 8, 2015
Kind
B2
Abstract

A fibronectin type III (Fn3) polypeptide monobody, a nucleic acid molecule encoding said monobody, and a variegated nucleic acid library encoding said monobody, are provided by the invention. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform said methods. Further provided is a method of identifying the amino acid sequence of a polypeptide molecule capable of binding to a specific binding partner (SBP) so as to form a polypeptide:SSP complex, and a method of identifying the amino acid sequence of a polypeptide molecule capable of catalyzing a chemical reaction with a catalyzed rate constant, k cat , and an uncatalyzed rate constant, k uncat , such that the ratio of k cat /k uncat is greater than 10.

Claims (21)

1. A nucleic acid molecule encoding a protein that comprises a fibronectin type III domain, wherein the fibronectin type III domain comprises at least two fibronectin type III β-strand domains with a loop region linked between each β-strand domain, wherein the integrin-binding domain has been removed from the FG loop of the fibronectin type III domain, wherein at least one loop region varies as compared to the wild-type fibronectin type III loop region by deletion of two to twelve amino acids in the loop region, insertion of at least two to 25 amino acids in the loop region, or replacement of at least two amino acids in the loop region, wherein at least one loop region binds to a specific binding partner (SBP) to form a polypeptide: SBP complex.

2. The nucleic acid molecule of claim 1 , wherein at least one loop region varies from the wild-type fibronectin type III loop region by the replacement of at least two amino acids in the loop region.

3. The nucleic acid molecule of claim 1 , wherein at least one loop region varies from the wild-type fibronectin type III loop region by the deletion of two to twelve amino acids in the loop region.

4. The nucleic acid molecule of claim 1 , wherein at least one loop region varies from the wild-type fibronectin type III loop region by the insertion of from 2 to 25 amino acids in the loop region.

5. The nucleic acid molecule of claim 1 , wherein the complex has a dissociation constant of less than 10 −6 moles/liter.

6. The nucleic acid molecule of claim 1 , wherein the amino acid sequence of at least one loop of the fibronectin type III domain is randomized in comparison with the corresponding a wild-type fibronectin type III loop region.

7. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule is DNA.

8. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule is RNA.

9. An expression vector comprising the nucleic acid molecule of claim 1 .

10. The expression vector of claim 9 , wherein the expression vector is an M13 phage-based plasmid.

11. An in vitro host cell comprising the vector of claim 9 .

12. A nucleic acid molecule encoding a protein that comprises a fibronectin type III domain, wherein the fibronectin type III domain comprises at least two fibronectin type III β-strand domains with a loop region linked between each β-strand domain, wherein the integrin-binding domain has been removed from the FG loop of the fibronectin type III domain, wherein at least one loop region varies as compared to the wild-type fibronectin type III loop region insertion of at least 2 to 25 amino acids in the loop region or replacement of at least two amino acids in the loop region, wherein at least one loop region binds to a specific binding partner (SBP) to form a polypeptide:SBP complex.

13. The nucleic acid molecule of claim 12 , wherein at least one loop region varies from the wild-type fibronectin type III loop region by the insertion of from 2 to 25 amino acids in the loop region.

14. The nucleic acid molecule of claim 12 , wherein at least one loop region varies from the wild-type fibronectin type III loop region by the replacement of at least two amino acids in the loop region.

15. The nucleic acid molecule of claim 12 , wherein the complex has a dissociation constant of less than 10 −6 moles/liter.

16. The nucleic acid molecule of claim 12 , wherein the amino acid sequence of at least one loop of the fibronectin type III domain is randomized in comparison with the corresponding a wild-type fibronectin type III loop region.

17. The nucleic acid molecule of claim 12 , wherein the nucleic acid molecule is DNA.

18. The nucleic acid molecule of claim 12 , wherein the nucleic acid molecule is RNA.

19. An expression vector comprising the nucleic acid molecule of claim 12 .

20. The expression vector of claim 19 , wherein the expression vector is an M13 phage-based plasmid.

21. An in vitro host cell comprising the vector of claim 19 .

Assignments (4)
CONFIRMATORY LICENSE Recorded Jan 30, 2020
From: UNIVERSITY OF ROCHESTER
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 051667/0618 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2013
From: KOIDE, SHOHEI
To: RESEARCH CORPORATION TECHNOLOGIES, INC.
Reel/Frame 030824/0040 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2013
From: RESEARCH CORPORATION TECHNOLOGIES, INC.
To: NOVARTIS INTERNATIONAL PHARMACEUTICALS LTD
Reel/Frame 030824/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2013
From: NOVARTIS INTERNATIONAL PHARMACEUTICALS LTD
To: NOVARTIS AG
Reel/Frame 030824/0065 →
Continuity (6)
Continuation 11981784 · Oct 31, 2007
Continuation 11410227 · Apr 24, 2006
Continuation 10190162 · Jul 3, 2002
Continuation 09096749 · Jun 12, 1998
Provisional Application 60049410 · Jun 12, 1997
Related Publication 20120135516A1 · May 31, 2012